Health Minister Mark Butler confirmed on 16 July 2026 that Ocrevus, Kesimpta and Lemtrada will remain subsidised on the Pharmaceutical Benefits Scheme, ending weeks of uncertainty for multiple sclerosis patients and their neurologists. Butler backed the drugs' continued PBS listing on clinical grounds, stating their therapeutic benefits justified ongoing government subsidy while a formal review of MS drug utilisation proceeds.

The reprieve is interim. The Pharmaceutical Benefits Advisory Committee, the independent expert body that advises government on PBS listings, has called for a rapid review of MS drug use to be completed before the end of 2026, at which point a final decision on the listings will be made.

The dispute that prompted Butler's intervention was triggered by the late-2025 addition of Briumvi, manufactured by TG Therapeutics, to the PBS at a cheaper cost than existing treatments. Under Australia's reference pricing system, the PBS ties the reimbursed price of drugs in the same therapeutic class to the cheapest option. Briumvi's lower price automatically pulled down the reference price for Kesimpta (Novartis) and Ocrevus (Roche), cutting what the government would pay for those established therapies.

Roche's general manager, Dr Nic Horridge, said the reference pricing cut "would make it impossible to keep Ocrevus on the PBS." That is the familiar pharmaceutical-industry line when reference pricing bites: the manufacturer signals it will withdraw supply rather than accept the reduced price, framing the withdrawal as commercially unavoidable. Whether the threat is a genuine deal-breaker or a negotiating posture is the question PBAC's rapid review will need to resolve before year's end.

The dollars involved explain why the manufacturers are twitchy. Under the PBS, a monthly dose of Kesimpta costs the Commonwealth AU$2,231. A course of ocrelizumab (Ocrevus) costs AU$16,500. In the United States, Kesimpta can cost more than US$10,000 per month. The contrast is stark, and it is precisely the comparison the PBS system is designed to produce: Australians pay a fraction of the US list price because the government negotiates as a single monopsony buyer. That leverage is the whole architecture of the scheme, and it is why reference pricing exists as a cost-containment tool.

The tension here is structural, not accidental. Reference pricing is the mechanism by which the PBS captures the benefit of new, cheaper entrants for the taxpayer: a lower-cost drug arrives, prices across the therapeutic class fall, and the government's bill shrinks. But if manufacturers of established drugs judge the new reference price below what they will accept, the mechanism can produce the opposite of its intent: fewer options on the scheme, not cheaper ones. Patients then either switch treatments or face full private cost.

ABC News reported on 8 July 2026 that the pricing dispute could result in Ocrevus and Kesimpta being pulled from the PBS, potentially leaving MS patients with large out-of-pocket costs. MS Australia publicly acknowledged that coverage via its official Facebook account the following day, signalling the patient advocacy sector was tracking the issue closely.

The inclusion of Lemtrada in Butler's confirmation is worth noting. Lemtrada was not directly caught in the Briumvi reference-pricing chain, and its appearance in the Minister's statement alongside Ocrevus and Kesimpta suggests the PBAC review will cast its net across the MS drug class broadly rather than confining itself to the specific products caught in Briumvi's pricing wake.

For the approximately 33,000 Australians living with MS, the immediate pressure is off. Ocrelizumab and ofatumumab remain accessible at PBS-subsidised rates. But the PBAC review timeline is tight, and the reference-pricing mechanism that created the problem is unchanged. A cheaper drug entering the class will continue to pull prices down for every other drug in it. The question for the review is whether the government can hold the cost-containment logic of reference pricing together with the clinical reality that patients on established therapies do not always tolerate or respond to alternatives.

Butler has, in effect, bought time. The clinical-benefit argument is sound as far as it goes: these drugs reduce relapse rates and slow disease progression in relapsing-remitting MS, and disrupting patients' treatment regimens carries genuine clinical risk. But "clinical benefit" is not a pricing mechanism. By year's end, PBAC will need to have reconciled the reference-price arithmetic with the therapeutic case for keeping multiple products listed, or Butler will be back at the dispatch box explaining why a cost-containment tool designed to save the PBS money has instead narrowed patient access.

The government's preferred outcome is obvious: Briumvi's cheaper price flowing through to lower PBS expenditure across the MS class, without any manufacturer walking away. Whether the manufacturers' threshold prices and the PBAC's reference price can converge on a number that delivers both is the only question that matters between now and December.